Evercore ISI Group Maintains Outperform on Cytokinetics, Raises Price Target to $80

Benzinga · 09/03/2025 13:38
Evercore ISI Group analyst Cory Kasimov maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $60 to $80.